CYMABAY THERAPEUTICS INC - COM (CBAY)

Historical Holders from Q3 2014 to Q2 2024

Symbol
CBAY
Type / Class
Equity / COM
All holders as of 30 Jun 2024
Q2 2024
Total 13F shares, excl. options
0
Holdings value
$0
Number of holders
0
Number of sells
-2
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of CYMABAY THERAPEUTICS INC - COM (CBAY)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q2 0 $0 -$1,303,383 0
2024 Q1 650 $21,077 -$2,704,600,701 $32.43 1
2023 Q4 114,757,534 $2,710,586,445 +$124,665,303 $23.62 198
2023 Q3 108,273,662 $1,614,512,313 +$248,853,575 $14.91 186
2023 Q2 92,788,933 $1,016,090,071 +$58,880,451 $10.95 148
2023 Q1 88,862,154 $774,919,455 +$217,014,250 $8.72 138
2022 Q4 63,439,729 $397,760,786 +$20,831,383 $6.27 115
2022 Q3 62,267,312 $217,873,004 -$2,093,777 $3.5 93
2022 Q2 63,013,354 $185,887,462 -$5,592,533 $2.95 96
2022 Q1 65,210,419 $202,829,241 +$4,287,026 $3.11 106
2021 Q4 63,819,650 $215,650,821 +$33,681,613 $3.38 107
2021 Q3 46,366,590 $169,293,393 -$24,483,402 $3.65 107
2021 Q2 52,158,607 $227,403,375 -$14,358,449 $4.36 108
2021 Q1 55,432,387 $251,650,727 -$7,053,547 $4.54 126
2020 Q4 56,362,930 $323,576,998 -$33,068,798 $5.74 140
2020 Q3 59,077,972 $428,045,235 +$20,308,782 $7.24 114
2020 Q2 59,822,943 $208,780,865 +$27,504,263 $3.49 108
2020 Q1 52,340,863 $77,465,816 -$4,311,446 $1.48 95
2019 Q4 58,132,775 $113,943,284 -$77,201,493 $1.96 108
2019 Q3 64,099,042 $328,177,512 -$24,948,443 $5.12 129
2019 Q2 67,803,698 $485,410,405 -$48,862,937 $7.16 130
2019 Q1 68,333,029 $907,454,217 +$143,542,378 $13.28 139
2018 Q4 58,228,856 $458,218,605 +$9,215,236 $7.87 125
2018 Q3 56,113,417 $621,728,888 -$4,917,454 $11.08 129
2018 Q2 56,251,498 $754,888,970 +$105,637,327 $13.42 113
2018 Q1 47,896,262 $619,498,039 +$188,545,396 $12.99 105
2017 Q4 34,079,994 $313,536,434 +$13,703,166 $9.2 80
2017 Q3 30,315,276 $244,131,974 +$155,113,903 $8.06 63
2017 Q2 11,286,449 $65,021,940 +$4,162,337 $5.76 37
2017 Q1 10,584,700 $45,497,983 +$18,951,201 $4.3 34
2016 Q4 6,983,292 $12,034,080 +$768,714 $1.73 25
2016 Q3 6,531,452 $12,668,286 -$1,140,536 $1.94 24
2016 Q2 7,117,001 $12,404,566 -$2,864,614 $1.74 21
2016 Q1 9,064,738 $12,238,611 -$2,403,427 $1.35 25
2015 Q4 10,753,196 $18,143,135 -$2,278,450 $1.69 27
2015 Q3 11,861,778 $22,968,985 +$8,855,507 $1.94 34
2015 Q2 6,725,971 $18,154,786 -$5,363,149 $2.69 28
2015 Q1 8,200,934 $56,749,719 +$912,988 $6.92 28
2014 Q4 7,658,912 $75,286,748 +$14,168,314 $9.83 25
2014 Q3 5,203,855 $35,592,000 +$35,592,000 $6.84 15